Table 2.
Overall survival of women with an advanced stage (II–IV) serous borderline ovarian tumor (SBT) in Denmark 1978–2002 relative to the general female population of same age in the same calendar year.
| n | Relative survival
|
Total number of
|
p-value* | ||||
|---|---|---|---|---|---|---|---|
| 5-year (95% CI) | 10-year (95% CI) | 15-year (95% CI) | Observed deaths | Expected deaths | |||
| Implants | |||||||
| Noninvasive | 114 | 95% (87.9–98.7) | 90% (80.7–95.7) | 83% (72.1–91.6) | 35 | 13.6 | <0.0001 |
| Invasive | 19 | 75% (46.6–91.9) | 60% (32.7–82.6) | 37% (13.6–63.8) | 13 | 2.0 | <0.0001 |
| Tumor type | |||||||
| SBT/APST | 113 | 94% (86.2–98.0) | 85% (75.8–92.4) | 77% (65.0–86.0) | 40 | 13.4 | <0.0001 |
| Noninvasive LGSC | 20 | 83% (57.3–95.7) | 87% (59.7–99.6) | 80% (51.4–98.3) | 8 | 2.1 | <0.0001 |
Abbreviations: atypical proliferative serous tumor (APST); low-grade serous carcinoma (LGSC); number (n); confidence interval (CI).
*
Total number of observed deaths among women with advanced stage (II–IV) SBTs compared with the total number of expected deaths in the general female population of same age in the same calendar year over the total follow-up period using the Score test.